R
Relievant Medsystems
Providing new solutions to the millions of patients suffering from chronic low back pain
About Relievant Medsystems
Relievant Medsystems, Inc. is dedicated to addressing chronic low back pain (CLBP), a condition affecting nearly 30% of the U.S. population at any given time. The company operates in the healthcare sector, specifically focusing on patients who suffer from vertebrogenic pain, a type of CLBP originating from the vertebral endplates and transmitted via the basivertebral nerve. Relievant's core product is the Intracept Procedure, a minimally invasive treatment designed to alleviate this specific type of pain. The procedure is backed by extensive research and clinical data demonstrating long-term relief for patients.
Relievant primarily serves patients, healthcare providers, and medical institutions. The company operates within the U.S. healthcare market, which sees approximately 52 million annual visits related to low back pain. Relievant's business model is centered around the commercialization of the Intracept Procedure, generating revenue through the sale of medical devices and associated services to healthcare providers and institutions.
The company makes money by selling its proprietary medical devices and offering training and support services to healthcare professionals who perform the Intracept Procedure. This approach not only provides a new revenue stream but also ensures the procedure's adoption and success in clinical settings.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2006
- Headquarters
- Minneapolis, United States
- Employees
- 193
- Open positions
- None listed
- Dealroom signal
- 65.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Sep 2023 | $850M | $850M | Boston Scientific | ↗ |
| SERIES GOther financing | Apr 2023 | $50M | $350M | Lightstone Ventures · Ally Bridge Group · NEA · Canaan | ↗ |
Growth signals
Latest recorded traffic for Relievant Medsystems is 440 monthly website visits, up 0% over the last three months. Relievant Medsystems's team declined 18.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Canaan- OVOnset Ventures
BCM Ventures
Series B and later8 investors entered at this stage
- MVMorgenthaler Ventures
- EPEmergent Medical Partners
NEA
Endeavour Vision
Lightstone Ventures
Emergent Ventures
Vensana Capital
Ally Bridge Group
Other known investors2 additional known investors
Boston Scientific
University of California, San Francisco
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Relievant Medsystems on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Relievant Medsystems’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.